Loading…

Abstract 13610: Examining Stroke in Metabolically Healthy Hospitalized Young Tobacco Users With Prediabetes: A Population-Based Analysis in the United States, 2019

Abstract only Introduction: Correlation between prediabetes and stroke risk among young, metabolically healthy tobacco users is unknown. Our research aims to explore this association. Methods: We did a retrospective study and extracted data from the 2019 National Inpatient Sample (NIS). Focusing on...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2023-11, Vol.148 (Suppl_1)
Main Authors: Desai, Rupak, Mahadevan, Arankesh, Dhavapalani, Dhayashri, Rajarajan, Srinishant, Babu, Kalaivani, Thompson-Edwards, Ashley, Reyaz, Nafisa, Garikipati, Sushmitha, Jain, Manisha, Meenashi Sundaram, Dakshin, Vanani, Samir, Prem Anand, Dharshana, Vasavada, Advait
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract only Introduction: Correlation between prediabetes and stroke risk among young, metabolically healthy tobacco users is unknown. Our research aims to explore this association. Methods: We did a retrospective study and extracted data from the 2019 National Inpatient Sample (NIS). Focusing on metabolically healthy (defined as absence of known cardiovascular disease risk factors, hypertension, diabetes mellitus, hyperlipidemia, and obesity) young adults aged 18-44 with tobacco use and prediabetes. Results: Our study of 1,017,540 hospital admissions of young, tobacco-using metabolically healthy individuals, identified 2,390 (0.2%) prediabetic cases. Compared to non-prediabetics, prediabetic patients were older, more often male, less frequently white, and had higher rates of comorbidities such as chronic obstructive pulmonary disease (19.2% vs. 11.7%), previous myocardial infarction (1.5% vs. 0.4%), and chronic kidney disease (2.5% vs. 0.9%). Clinical outcomes showed prediabetes was associated with higher rates of major adverse cardiac and cerebrovascular outcomes (MACE) (2.9% vs. 1.4%, p
ISSN:0009-7322
1524-4539
DOI:10.1161/circ.148.suppl_1.13610